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ABSTRACT 
Biochemical assessments of androgen status (hyper- or hypoandrogenism) are usually based on 
serum testosterone concentrations. According to the free hormone hypothesis, sex hormone-binding 
globulin (SHBG) determines free and bioavailable testosterone concentrations. Previous studies have 
suggested that in vitro androgen bioassay results may also be influenced by SHBG and correlate with 
free or bioavailable testosterone concentrations. To test this hypothesis, we established a stable 
HEK293 cell line with high expression of the human androgen receptor (AR) and a luciferase reporter 
downstream of a classical androgen response element. Importantly, we demonstrate that bioassay 
results are sensitive to dilution effects which increase apparent bioactivity in an SHBG-dependent 
manner. We therefore adopted a method using undiluted serum, which reduced cell proliferation but 
did not significantly affect the luciferase signal, cell viability or cytotoxicity. To correct for serum matrix 
effects, we applied signal correction based on internal controls with AR agonists or antagonists. Using 
this method, we provide direct evidence that in vitro androgen bioactivity reflects the inhibitory effects 
of SHBG, and correlates with free or bioavailable testosterone concentrations in adult hypogonadal 
men receiving androgen replacement therapy. In men receiving anti-androgens, serum bioactivity 
decreased tenfold while serum testosterone concentrations decreased only four-fold. Further pilot 
results in prostate cancer patients showed that androgen synthesis inhibitors result in more complete 
inhibition of androgen bioactivity than gonadorelin-based androgen deprivation therapy, even in 
patients whose testosterone concentrations were undetectable by mass spectrometry. We conclude 
that in vitro androgen reporter bioassays are useful tools to study how androgen bioactivity in serum is 
determined by androgens, anti-androgens as well as SHBG, provided that dilution and matrix effects 
are accounted for. 
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1. INTRODUCTION 
Androgens are endogenous C19 steroid hormones which activate the androgen receptor (AR) and 
elicit important biological functions in reproductive and other sexually dimorphic tissues (Pihlajamaa et 
al., 2015). Upon ligand binding in the cell cytoplasm, the AR dimerizes, translocates to the nucleus, 
binds to specific DNA sequences called androgen response elements (AREs) and recruits co-
regulators to activate transcription of its target genes (Helsen and Claessens, 2014, Pihlajamaa et al., 
2015). Two types of AREs exist: classical and selective AREs, which are either conserved or partially 
conserved repeats of the 5’-AGAACA-3’ consensus sequence separated by a three-nucleotide spacer. 
Classical AREs can be recognized by other nuclear receptors like the glucocorticoid or progesterone 
receptor, while only AR can bind selective AREs to elicit transcriptional programs specific to e.g. male 
reproductive organs (Denayer et al., 2010, Kerkhofs et al., 2012, Pihlajamaa et al., 2015, Sahu et al., 
2014, Schauwaers et al., 2007). 
The AR is mainly a ligand-dependent transcription factor whose biological effects largely depend on 
the time and degree of AR occupancy by different ligands (Clinckemalie et al., 2012). Serum 
testosterone (T) concentrations are the primary method to judge androgen status in clinical practice 
(Snyder et al., 2016). In addition to T and its more active metabolite, 5α-dihydrotestosterone (DHT), 
androst-4-ene-3,17-dione (Adione) or androst-5-ene-3β,17β-diol (Adiol) are endogenous androgens or 
androgen precursors that are also present in the circulation, and recent studies suggest that 
measuring these androgens may also contribute to the assessment of androgen bioactivity (Munzker 
et al., 2015, O'Reilly et al., 2014). Importantly, the bioavailability of circulating sex steroids is thought 
to be inhibited by sex hormone-binding globulin (SHBG) (Mendel, 1989). This ~45 kDa glycoprotein 
has high (nM Kd) binding affinity for DHT, T and estradiol (E2) (Wu and Hammond, 2014). On average, 
about 45% of circulating T or E2 is bound to SHBG in normal adult men and women, respectively. This 
fraction is considered biological unavailable, while non-SHBG-bound steroids constitute the 
bioavailable fraction. This bioavailable fraction is mainly bound with low affinity to bulk carrier proteins 
like albumin and only 1-3% circulates freely (i.e. non-protein-bound) (Dunn et al., 1981, Hammond et 
al., 2012, Rosner et al., 2007, Siiteri et al., 1982, Vermeulen et al., 1999). According to the free 
hormone hypothesis however, only non-protein-bound or “free” steroid hormones can diffuse into 
target cells and activate their cognate nuclear receptor (Mendel, 1989). Thus, SHBG is regarded as an 
important regulator of circulating sex steroid bioactivity. In clinical practice, free T and/or bioavailable T 
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(bioT) and E2 concentrations are routinely calculated from total sex steroid and SHBG concentrations 
(Rosner et al., 2007, Rosner et al., 2013). However, growing concern surrounds this approach 
(Heinrich-Balard et al., 2015, Laurent and Vanderschueren, 2014, Zakharov et al., 2015). For 
example, several non-synonymous single nucleotide polymorphisms (SNPs) in the SHBG gene have 
been identified recently which may influence androgen binding affinity and thus free T concentrations 
(Ohlsson et al., 2011, Wu and Hammond, 2014). 
The golden standard to measure androgen bioactivity is an in vivo androgen bioassay called the 
Hershberger test, which involves test compound administration to castrated rats and post-mortem 
evaluation of the animals’ accessory sex organs (Marty and O'Connor, 2014). In vitro bioassays can 
replace the use of laboratory animals to a certain extent, but their main advantage is that they are 
more practical for high-throughput screenings (Roy et al., 2008, Voet et al., 2013), screening for 
steroid abuse in athletes (Bailey et al., 2016, Cooper et al., 2013) or for potentially endocrine-
disrupting compounds in environmental samples (Christiaens et al., 2005). In vitro bioassays can be 
classified as proliferation assays (e.g. proliferation response of an androgen-sensitive prostate cancer 
cell line) or reporter assays (e.g. based on transactivation of a luciferase construct, which offers more 
direct evidence of AR-mediated signaling). Furthermore, bioassays have been established using 
different mammalian or yeast cell lines; the latter may provide an advantage when metabolism and 
detection of precursor androgens like Adione, Adiol and dehydroepiandrosterone (DHEA) is desired 
(e.g. for hormone abuse screening in livestock or athletes), although the thick yeast glycocalyx may 
hinder diffusion into target cells (Soto et al., 2006). 
In vitro bioassays are most used for screening compounds in drug development or endocrine disruptor 
research, but they have also been applied to study circulating androgen bioactivity (Roy et al., 2008). It 
has been suggested that results from in vitro androgen bioassays also reflect the influence of SHBG 
(Liimatta et al., 2014, Raivio et al., 2001, Roy et al., 2006), but this has not been tested directly. One 
concern in this regard is the fact that most AR bioassays are conducted in the presence of diluted 
serum samples to 1-10% (with one notable exception using undiluted serum (Need et al., 2010). 
Previous studies on equilibrium dialysis have shown that dilution may disturb the equilibrium between 
SHBG and its ligands (Van Uytfanghe et al., 2004), but whether dilution also affects AR bioassay 
results is not known. Another important factor identified previously are matrix effects (Paris et al., 
2002a, Roy et al., 2006) that are well known in clinical chemistry. Matrix effects can be defined as 
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serum sample components which are unrelated to the analyte of interest per se (in this case, 
androgen bioactivity) but still produce unwanted alterations of the bioassay read-out. Considering this 
background, the aim of this study was to establish an androgen reporter bioassay to study the effects 
of SHBG on androgen bioactivity in vitro, and to validate our bioassay method in pilot studies using 
patient samples with particular attention to dilution and matrix effects. 
2. MATERIALS AND METHODS 
2.1. Hormones and chemicals 
T, DHT, Adiol, Adione, R1881 (methyltrienolone), mibolerone, medroxyprogesterone acetate, E2, 
progesterone, dexamethasone, hydrocortisone, DHEA and DHEA-sulphate, ethanol, dimethylsulfoxide 
(DMSO) and ionomycin were purchased from Sigma-Aldrich. MENT (7α-Methyl-19-Nortestosterone) 
was a kind gift from dr. N. Kumar of the Population Council (New York, NY, U.S.A.). Enzalutamide was 
purchased from Sequoia Research Products (Pangbourne, U.K.). 
2.2. Cell lines and culture conditions 
Human embryonic kidney (HEK)-293 and VCaP cells were obtained from the American Type Culture 
Collection (Manassas, VA) and cultured as described before (Haelens et al., 2001). 
2.3. Stable cell line selection 
HEK-293-based T-Rex
®
 cell lines stably expressing four copies of three different classical or selective 
AREs were selected with hygromycin (50 µg/mL, Thermo Fisher Scientific, Waltham, MA, U.S.A.) as 
described previously (Denayer et al., 2010). Cells were subsequently transfected by random 
integration with a full-length human AR cDNA construct inserted into the pSG5 vector (Christiaens et 
al., 2005) using GeneJuice® (Novagen, Merck, Darmstadt, Germany) as previously described (De 
Bruyn et al., 2011). The next day, cells were sparsely seeded in 6-well plates. Following selection with 
G418 (600 µg/mL, Thermo Fisher Scientific, Waltham, MA, U.S.A.), colonies showing androgen-
induced luciferase activity were screened using firefly D-Luciferin-containing medium (150 µg/mL, 
Caliper Life Sciences) on the IVIS bioluminescence system. Isolated, luciferase-positive colonies were 
picked, clonally expanded and evaluated for androgen-induced luciferase activity. AR protein 
expression was verified by Western immunoblotting on whole-cell extracts. 
2.4. Luciferase experiments 
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LARA cells were cultured in phenol-red free Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L 
glucose (Thermo Fisher Scientific, Waltham, MA, U.S.A.), supplemented with 10% fetal calf serum, 
penicillin, streptomycin and glutamin as described (Christiaens et al., 2005). Following trypsinization, 
cells were counted with a TC-20 Automated Cell Counter (Bio-Rad, Hercules, CA, U.S.A.) and seeded 
at 5’000 cells/well in similar media with 5% dextran-coated charcoal-stripped FCS (DCC-FCS) into 
half-area 96-well cell culture plates (Greiner Bio-One, Kremsmünster, Austria). The next evening, 
media were replaced with various serum, medium and hormone concentrations as described below. T 
standard curves were prepared in 10-12 different T concentrations in undiluted DCC-FCS, and 
concentrations were validated by in-house liquid chromatography tandem mass spectrometry (Antonio 
et al., under review). Each standard and unknown was analyzed using six replicate wells. The minimal 
optimal volume was determined at 10 µL/well (data not shown). As an internal control for matrix 
effects, each patient serum sample was analyzed after spiking with either DHT 10
-6
 M or enzalutamide 
10
-5
 M as an internal control to adjust the corresponding 1:1000 vehicle-spiked sample for matrix 
effects (see Fig. 4, Suppl. Fig. 3 and Fig. 5 below, respectively). After 14-16h of incubation, media 
were removed, cells were lysed and arbitrary luciferase units (ALU) were quantified as described (De 
Bruyn et al., 2011) on a Luminoskan Ascent microplate luminometer (Thermo Fisher Scientific). The 
results were analyzed as described in the statistics section below. 
2.5. Cell viability and toxicity assays 
Cell viability was assessed by XTT assay (Applichem, Darmstadt, Germany) and cytotoxicity was 
assessed using the CellTox™ Green dye (Promega, Fitchburg, WI, U.S.A.) according to the 
manufacturer’s instructions. 
2.6. Thymidine incorporation assay 
Cell proliferation was assessed by measuring 
3
H-labelled thymidine incorporation as a surrogate of 
DNA replication. LARA cells were seeded in 96-well plates (Cellstar; Greiner Bio-One) in medium 
containing 10% DCC-FCS. The next evening, media were replaced by different percentages of human 
serum supplemented with 
3
H-thymidine (PerkinElmer, Waltham, MA, U.S.A.). Sixteen hours later, 
media were removed and cells were rinsed, followed by trypsinization and transfer to a new multiwell 
plate using a cell harvester (Filtermate 196, Packard, Meriden, CT, U.S.A.). Fifty microlitres of liquid 
scintillation fluid (Microscint-O, Packard) was added to each well and disintegrations were counted 
using a microplate scintillation counter (Packard Topcount) as described previously (Helsen et al., 
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2012). Measurements were corrected for background in wells without cells (<1%) as well as values of 
input media used for stimulation, and expressed as percentage of the 5% serum condition.  
2.7. SHBG protein 
Since most mammals except mice and rats express Shbg post-natally in their livers, we obtained 
serum from six Wistar rats castrated for 3 weeks, as well as from heterozygous human SHBG-
transgenic (Jänne et al., 1998) and wild-type control littermate male mice. Two mice of each genotype 
were orchidectomized at 20 weeks of age. Following euthanasia at 24 weeks, serum was obtained by 
cardiac puncture and pooled per genotype. The Animal Ethical Committee of KU Leuven approved all 
procedures (P160/2012), and mice were bred and used in accordance with current Belgian national 
and European directives. Serum from the orchidectomized rats was spiked with either 1.6% serum of 
castrated SHBG-transgenic mice (to obtain a 50 nM SHBG final concentration) or 1.6% serum from 
wild-type mice, to obtain a pure serum matrix with or without human SHBG. Both sera were spiked 
with 10 nM T and tested for androgen bioactivity either undiluted or at various serum dilutions as 
described below (see Fig. 2A below). A similar setup using serum of orchidectomized rats and 
orchidectomized SHBG-transgenic and WT mice was used to test the effect of SHBG on various 
hormone mixtures in undiluted serum (see Fig. 3C below). Alternatively, recombinant human SHBG 
(>95% purity SDS-PAGE from Alpha Diagnostic Intl. Inc., San Antonio, TX, USA) was added to serum 
from a recently described man with complete SHBG deficiency (Vos et al., 2014) (see Fig. 3A below). 
To test the effect of SHBG mutants, HEK-293 cells were transiently transfected as described above 
with expression plasmids for SHBG WT, R123H, R123C, T7N, S42L, P156L or the empty pRc/CMV 
vector as described previously (Avvakumov et al., 2010, Hong et al., 2011, Ohlsson et al., 2011, Wu 
and Hammond, 2014). Two days after transfection, conditioned media were collected and 
concentrated using Amicon Ultra-4 centrifugal ultrafiltration units with 30’000 molecular weight cut-off 
filters (Merck Millipore). 
2.8. Patient samples 
Following approval by the University Hospitals Leuven Medical Ethical Committee (s54034, 
ClinicalTrials.gov number NCT02434562), a prospective biobank was set up to obtain serum for 
analysis. All patients provided written informed consent. Men starting androgen deprivation or 
replacement therapy were recruited from the Department of Endocrinology and prostate cancer 
patients were recruited from the Department of Urology, University Hospitals Leuven, Belgium. Human 
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serum was obtained from two healthy male volunteers undergoing maintenance flebotomy for well-
controlled hereditary hemochromatosis without end-organ complications. 
2.9. Testosterone and SHBG measurements 
Serum T and SHBG concentrations were measured on a Roche Modular E clinical immunoassay 
platform at the Department of Laboratory Medicine of the University Hospitals Leuven. T was 
measured with an in-house liquid chromatography tandem mass spectrometry (LC-MS/MS) method 
based on atmospheric pressure chemical ionisation (Antonio et al., manuscript submitted) with a limit 
of quantification of 2.5 ng/dL for total T and imprecision <5%. Free T and bioT were calculated 
according to (Vermeulen et al., 1999) with albumin fixed at a constant 4.3 g/dL using the online 
calculator at http://www.issam.ch/freetesto.htm . The SHBG concentrations in conditioned media from 
cells transfected with various SHBG expression plasmids were cross-validated by measurement on a 
different clinical immunoassay platform (Siemens Immulite 2000) as well as by Western blot using an 
in-house primary polyclonal rabbit anti-human SHBG antiserum (1:100 diluted in 3% milk protein) 
obtained using standard techniques (Marivoet et al., 1990). 
2.10. Statistical analyses 
All analyses were performed using Graphpad Prism v5.04. Mean and standard error (SEM) of 2-3 
experiments are shown as specified. Standard curves were fitted with asymmetric (Richard’s five-
parameter) dose-response curves using 1/Y² weighing and interpolation of individual unknowns. The 
luciferase values obtained from unknown samples were interpolated on the T standard curves and 
expressed as “T bioequivalents”, defined as the corresponding T concentration for a certain luciferase 
value on the T standard curve. We corrected for matrix effects in the experiment with different 
conditioned media of cells transfected with SHBG mutants (Fig. 3B) using the luciferase values 
observed after spiking with 10
-6 
M R1881 (which did not however influence the results, data not 
shown). Patient samples (see Fig. 4) were corrected for matrix effects by dividing each replicate by the 
ratio between the 10
-6
 M DHT-spiked serum sample average and the 10
-6
 M DHT- or T-spiked DCC-
FCS average (see also Suppl. Fig. 3). Differences in continuous variables were analyzed using one-
way ANOVA with Bonferroni’s post-test, or Kruskal-Wallis test with Dunn’s multiple comparisons test 
when variances were unequal. For categorical variables, differences in proportions were assessed by 
chi-square (χ²). For experiments involving matched values, differences in one continuous variable 
between two or more groups were analyzed by Wilcoxon matched-pairs signed rank test or repeated 
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measures (RM) ANOVA with Dunnett’s post-test, respectively. To study interaction between two 
variables, two-way RM ANOVA with Bonferroni’s multiple comparisons post-test was used. 
Correlations were examined using Pearson’s r and linear regression following runs test to examine 
deviation from linearity. Significance was considered at two-tailed P≤0.05. 
 
3. RESULTS 
3.1. Bioassay development and characterization 
In general, cell lines with the classical ARE (from ADAMTS1,A) showed higher luciferase activity 
compared to those transfected with selective AREs (from the TMPRSS2 or PDE9A genes) 
(Supplementary Fig. 1A). The colony with highest sensitivity and high induction factors (arrow in 
Supplementary Fig. 1B; light green line in Fig. S1A) was selected and termed LARA, for Luciferase 
Androgen Reporter Assay. Fig. 1A shows the luciferase activity in response to various T 
concentrations on three representative standard curves. The detection limit for T, defined as the first 
standard point with luciferase activity more than three standard deviations above vehicle control, was 
10
-9.5
 M (0.3 nM) and EC50 was 10
-7.7
 M (20 nM). LARA responded as expected to synthetic 
androgens, various endogenous androgens as well as to supraphysiological concentrations of E2, 
progesterone or glucocorticoids (dexamethasone), and not to precursors or metabolites like 
dehydroepiandrosterone (DHEA) or DHEA-sulphate (DHEAS) (Fig. 1B). These data are in line with 
the known affinity of these ligands for the AR. Western immunoblot (Fig. 1C) confirmed high AR 
protein expression in the LARA cell line compared to (i) the AR-negative, ADAMTS1,A-ARE-Luc-
positive parental HEK cell line, (ii) the AR-positive VCaP prostate cancer cell line and (iii) a previously 
established classical ARE (ClARE) cell line designed for compound screening (Helsen et al., 2012) 
(Fig. 1D). 
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Fig. 1. Androgen bioassay characterization. 
A. Three representative standard curves showing log-transformed arbitrary luciferase units (ALU) values in 
response to different T concentrations or vehicle (V) in undiluted DCC-FCS. Means ± SEM of six replicate wells 
along with their fitted curve are shown. 
B. Luciferase response (relative luciferase units [RLU]) to different hormones (n=3 experiments). As expected, the 
classical ARE of LARA confers responses not only to natural (T, DHT, as well as Adiol and Adione at 
supraphysiological concentrations) and synthetic androgens (mibolerone, MENT, R1881 and the weaker 
medroxyprogesterone acetate, MPA), but also to pharmacological doses of progesterone, dexamethasone and 
E2. 
C. Representative Western blot of whole cell extracts from (i) the parental ADAMTS1,A-ARE-Luc(+), AR(-) HEK 
cell line, (ii) the VCaP prostate cancer cell line, (iii) LARA cells and (iv) a previous AR bioassay cell line (ClARE) 
(Helsen et al., 2012). 
D. Quantification of protein expression, normalized to GAPDH control and expressed as % of ClARE values (n=3 
experiments). 
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3.2. Effect of serum dilution on androgen bioassay results and performance 
To test whether serum dilution affected apparent in vitro androgen bioactivity, we prepared 96-well 
plates with standard curves and samples at different serum concentrations. On each plate, we 
measured two samples: serum of castrated rats spiked with 10 nM T and either 1.6% serum from 
castrated human SHBG-transgenic mice (=50 nM human SHBG) or 1.6% serum from castrated WT 
mice (Jänne et al., 1998). This experimental design takes advantage of the fact that castration not only 
removes the major source of circulating androgens but also of any SHBG that may leak into the 
circulation from behind the blood-testis barrier. Indeed, Shbg expression in WT mice and rats is also 
limited to the testis and not secreted from the liver into the circulation (Gunsalus et al., 1978). The 
results showed that while in the control condition (without SHBG) the measurements were unaffected 
by dilution, the apparent androgen bioactivity was significantly increased at 5% and 10% serum 
compared to undiluted serum in an SHBG-dependent fashion (Fig. 2A). 
To investigate whether use of undiluted serum was possible, we incubated LARA cells with increasing 
serum concentrations. Applying 100% human serum overnight resulted in altered (“bloated”) cell 
morphology compared to 10% FCS or 10% human serum (Fig. 2B). Quantitatively however, 
increasing serum concentrations were not detrimental but rather increased luciferase activity using 
unspiked human male serum (Fig. 2C). The rising absolute luciferase activity could be attributed to 
increasing absolute androgen concentrations in less diluted serum, since luciferase activity remained 
stable when using a pool of serum from prostate cancer patients under androgen deprivation therapy 
(ADT). Likewise, the background luciferase signal in the parental ADAMTS1,A-ARE-Luc(+), AR(-) cell 
line remained stable up to 100% serum (Fig. 2D). Similarly, the number of viable cells as determined 
by XTT assay was not significantly different between 10% and 100% serum (Fig. 2E). However, since 
cell number is determined by both cell proliferation and cell death, we evaluated these components 
individually. DNA replication as measured by 
3
H-thymidine incorporation was significantly reduced at 
higher serum percentages (Fig. 2F). Cytotoxicity as measured with the CellTox™ Green dye was 
slightly but significantly higher at 50% and 80% (Fig. 2G), but this is probably due to greater cell 
number. However there was no significant difference between 10% and 100% serum, and in any case 
these differences were marginal compared to the effect of ionomycine as a positive control (Fig. 2H). 
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Fig. 2. Effect of serum dilution on in vitro bioassay performance. 
A. In the condition without SHBG (dotted curve, triangles), measurements are unaffected by serum sample 
dilution. In the presence of SHBG (full line, circles), apparent androgen bioactivity is increased at higher dilutions 
(lower serum fractions: 
++
 = P≤0.01 and 
++++
 = P≤0.0001 for 5% and 10% serum vs. 100% serum in the same 
group, respectively). * = P ≤ 0.05, ** = P ≤0.01, *** = P≤0.001 for effect of SHBG vs. control at the same dilution 
(note that at 5% serum, a significant effect of SHBG can no longer be detected). Analysis by two-way RM ANOVA 
of n=3 experiments, P<0.0001 for effect of dilution, P=0.01 for effect of SHBG and P=0.0008 for interaction. 
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B. Representative microphotographs of LARA cells in culture with 10% FCS, after overnight incubation with 10% 
human serum (HS) and with 100% HS. Bar inset = 0.1 mm. 
C. Relative luciferase units (RLU, induction factors) normalized to 5% serum condition. By two-way RM ANOVA, 
there was a significant effect of serum dilution (P<0.0001), androgen deprivation (P=0.02) with evidence of 
interaction (P<0.0001), n=2 experiments. Bonferroni post-tests showed ** = P ≤ 0.01, **** = P < 0.0001 for HS vs. 
ADT serum at the same dilution, ++ = P ≤ 0.01, ++++ = P < 0.0001 for difference compared to 10% serum within 
the same type of serum. 
D. Background luciferase activity (shown as RLU i.e. normalized to 5% serum condition) in the parental ARE-
positive, AR-negative HEK cell line. No significant differences by two-way RM ANOVA, n=3 experiments.  
E. Cell viability (normalized to 5% serum condition) determined by optical density (OD) at 450 nm of the 
colorimetric XTT assay. No significant differences by two-way RM ANOVA, n=2 experiments. 
F. Thymidine incorporation (expressed as counts per minute, cpm and normalized to 5 serum condition) in 
response to 16h stimulation with various male serum concentrations. ** = P ≤ 0.01 by Dunnett’s post-test after 
one-way RM ANOVA (overall P=0.002), n=3 experiments. 
G. Cytotoxicity as determined by arbitrary fluorescence units (AFU) in the CellTox Green assay in response to 
increasing human serum sample concentrations. * = P ≤ 0.05 by Dunnett’s post-test after one-way RM ANOVA 
(overall P=0.008), n=3 experiments. 
H. Cytotoxicity in response to increasing ionomycine concentrations. ** = P ≤ 0.01, *** = P ≤ 0.001 by Dunnett’s 
post-test after one-way RM ANOVA (overall P<0.0001), n=3 experiments. 
 
3.3. Effect of WT and mutant SHBG on androgen bioactivity in vitro 
To study the effects of human SHBG on in vitro androgen bioactivity in an undiluted serum context, we 
obtained serum from a recently described SHBG-deficient man, who presented with low total but 
normal free T serum concentrations (Vos et al., 2014). In vitro androgen bioactivity appeared to be in 
the low-normal range in this man (Fig. 3A, compare to Fig. 4A-B below) and was significantly 
decreased by adding recombinant human SHBG. 
Several SHBG mutants have been described which display altered affinity constants for T and DHT 
(Hogeveen et al., 2002, Ohlsson et al., 2011, Wu and Hammond, 2014). We obtained these mutants in 
concentrated conditioned media from HEK cells transfected with different expression plasmids. Mutant 
P156L was consistently produced at lower levels, therefore a more concentrated matrix was used. 
However all mutants were recognized similarly by the two clinical immunoassay platforms (data not 
shown). Western blot using an in-house polyclonal rabbit anti-human SHBG antiserum suggested that 
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two mutants (G195E and T48I) were present in the media (Supplementary Fig. 2) despite being 
present in low to undetectable concentrations using the Roche immunoassay, therefore these two 
mutants were probably underrecognized by the monoclonal antibody and not analyzed in further 
experiments. When tested in our bioassay, both SHBG WT and T7N (which has altered glycosylation 
but normal binding affinity) reduced androgen bioactivity. This reduction was less pronounced when 
using a mutant that is completely binding deficient (S42L) or a mutant with 4.3-fold lower androgen 
binding affinity (R123H). No difference could be detected with the R123C or P156L mutants, for which 
modest alterations in binding affinity have been reported (1.6-fold lower for R123C and 2-fold lower 
affinity for P156L) (Fig. 3B). 
Next, we examined the effect of SHBG on the in vitro androgen bioactivity of different sex steroids 
alone or in combination at (male) physiological concentrations. For this experiment, we used undiluted 
serum from orchidectomized rats and orchidectomized SHBG-transgenic or WT male mice spiked with 
varying hormone concentrations (see Materials and methods). The rationale for this experiment was 
that different sex steroids have different affinities not only for AR but also for SHBG, and therefore it 
has been suggested that the balance between different ligands could be altered in the presence of 
SHBG (i.e. because one ligand competes another off of SHBG, making it more accessible for AR, for 
example). We found circulating androgen bioactivity to be determined not only by T but also by DHT, 
whereas Adiol and Adione or E2 at physiological concentrations had no effect. SHBG significantly 
reduced the androgen bioactivity of DHT more so than that of T, however with no additional 
differences or interactions from other endogenous sex steroids (Fig. 3C). Thus, SHBG did not appear 
to modify the balance between different endogenous sex steroids at male physiological concentrations 
in a pure serum context in vitro. 
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Fig. 3. Effects of SHBG on in vitro androgen bioactivity. 
A. In vitro androgen bioactivity in serum from an SHBG-deficient man (Vos et al., 2014), without and with 
increasing recombinant human SHBG concentrations. * = P < 0.05 by Bonferroni post-test after one-way RM 
ANOVA (overall P<0.05), n=3 experiments. 
B. Effect of recombinant SHBG WT and different mutants on the bioactivity of ~20 nM T in DMEM containing 10% 
DCC-FCS and conditioned media at various dilutions to obtain 50 nM SHBG final concentration in all conditions. 
Results adjusted for matrix effects using values after spiking with R1881 10
-6
M. ** = P≤0.01, *** = P≤0.001 by 
Dunnett’s post-test after one-way RM ANOVA (overall P<0.0001), n=3 experiments. 
C. Androgen bioactivity expressed as T bioequivalents (in nM) in response to physiological male concentrations of 
E2 (0.1 nM), T (17 nM), DHT (1 nM), Adiol and Adione (each 3 nM) alone or in combination, and either in the 
presence or absence of 50 mM recombinant WT human SHBG, in undiluted serum of orchidectomized rats (see 
Materials and Methods). * = P≤0.05, **** = P<0.0001 for significant induction compared to vehicle control in the 
absence of SHBG, + = P≤0.05 for effect of SHBG compared to the same hormone group without SHBG. Analysis 
by two-way RM ANOVA of n=2 experiments, P<0.0001 for effect of different hormones, P<0.0001 for effect of 
SHBG and P=0.02 for interaction. 
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3.4. Pilot study on androgen bioactivity in hypogonadal men 
Twelve prospectively recruited men (median 47.5 years, range 19-75 years) started androgen 
deprivation therapy (ADT) for either paraphilias (n=6), hypersexual behavior (n=3) or cross-sex 
hormone treatment (n=3). Of these 12 patients, 11 started treatment with cyproterone acetate (CPA) 
50-100 mg/day (Androcur®, an anti-androgen which also decreases gonadotropin concentrations and 
androgen synthesis via its progestagenic effects). Androgen bioactivity decreased in all of these 
patients from median 17.5 nM (interquartile range 11.2-30.9) to 1.4 nM (IQR 1.15 – 1.58), and this 
>10-fold reduction was overall significant (Wilcoxon matched-pairs signed rank test, P=0.001) (Fig. 
4A). In comparison, serum T concentrations in these patients only reduced ~4-fold from median 462.2 
ng/dL (IQR, 320.3 – 528.4) to 106.9 ng/dL (IQR 45.3 – 162.3). One patient with incomplete 
biochemical response to CPA (serum T 187.7 ng/dL) and persistent symptoms despite CPA 150 
mg/day was switched to the gonadoreline analogue triptoreline (Salvacyl®). This reduced his 
androgen bioactivity from 2.7 to 0.5 nM T bioequivalents. 
Twelve other prospectively recruited male hypogonadal patients (median 53.5 years, range 38-77) 
started androgen replacement therapy with either transdermal or intramuscular T (Androgel® or 
Sustanon®, n=6 each). Serum T concentrations were median 184 ng/dL (IQR 132.6 – 278) at baseline 
and 316.5 ng/dL(IQR 248.4 – 397.1) at follow-up visit. Compared to the normal male reference range 
for SHBG (24-55 nmol/L), four men had low and three had high SHBG at baseline or follow-up 
(n=11/24 samples in total). Androgen bioactivity increased in 10/12 patients from a median 5.9 (IQR 
4.9-9.8) to 11.8 (IQR 8.0-15.0) nM T bioequivalents (Wilcoxon matched-pairs signed rank test, 
P=0.0049) (Fig. 4B). Androgen bioactivity in these patients correlated significantly (P<0.0001) with 
both calculated bioT as well as free T (Fig. 4C-D). In contrast, total T was only moderately associated 
with bioactivity (R²=0.29, P=0.007) (Fig. 4E), particularly considering that total T and bioT were also 
correlated (P<0.0001, R²=0.64) (not shown). 
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Fig. 4. In vitro androgen bioactivity in hypogonadal men. 
A. Androgen bioactivity (expressed as nM T bioequivalents) in n=12 men before and after androgen deprivation 
therapy. *** = P=0.001 by Wilcoxon matched-pairs signed rank test. 
B. Androgen bioactivity in n=12 men before and after androgen replacement therapy. ** = P=0.0049 by Wilcoxon 
matched-pairs signed rank test. 
C-E. Correlation of bioT, free T (calculated according to (Vermeulen et al., 1999)) or total T with in vitro androgen 
bioactivity in men before and after androgen replacement therapy (n=24 samples in total). The Vermeulen formula 
for free T or bioT is based on a linear law of mass action equation assuming a fixed SHBG affinity constant and 
using as input variables the observed concentrations of  total T, SHBG and/or albumin. The 95% confidence band 
of the linear regression is shown as a dotted line. 
 
On two different 96-well plates, most patient samples (before or after androgen replacement therapy) 
spiked with DHT 10
-6 
M showed values that were significantly higher than the maximal signal obtained 
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with 10
-6
 M T or DHT in DCC-FCS. This can only be explained by matrix effects of serum that were 
found to be mostly positive matrix effects, i.e. increasing the luciferase signal, except in one sample 
(Supplementary Fig. 3). 
3.5. Pilot study on androgen bioactivity in prostate cancer patients 
Forty-nine prospectively recruited prostate cancer patients (median age 75 years, range 61-87 years) 
provided serum for analysis. These patients were treated with either androgen deprivation therapy 
(ADT, n=24 of which n=21 gonadorelin analogues and n=3 gonadorelin antagonists), dual androgen 
blockade (ADT + bicalutamide, Bic n=16), androgen synthesis inhibitors (Synth-I: n=3 orteronel, n=2 
abiraterone, n=1 ketoconazole; all with add-on glucocorticoids) or Bic monotherapy (n=2), and one 
was treatment-naive (pre-ADT). Serum total T concentrations measured by LC-MS/MS in different 
groups are shown in Fig. 5A. Except for one patient, all men treated with ADT or ADT+Bic had serum 
T < 50 ng/dL (and even < 20 ng/dL). The proportion of samples with T concentrations below the LC-
MS/MS limit of quantification (<5.0 ng/dL) was greater in the Synth-I group (6/6) than in the ADT or 
ADT+Bic groups (3/24 and 1/16 respectively; both χ² P<0.0001) (Fig. 5A). These results are based on 
LC-MS/MS because serum T measured by immunoassay showed considerable disagreement 
between these methods at concentrations <50 ng/dL (Fig. 5B). Serum T was undetectable by 
immunoassay in 13/24 ADT and 2/16 ADT+Bic patients, but this was confirmed by LC-MS/MS only in 
3/13 and 0/2 patients, respectively. Conversely, serum T was below the LC-MS/MS limit of 
quantification in 3/24 ADT and 1/16 ADT+Bic patient, all of which were confirmed by immunoassay. 
We compared the ADT and Synth-I groups (n=2 were excluded from the ADT group due to insufficient 
remaining serum) in the bioassay, in the absence or presence of the potent anti-androgen 
enzalutamide. Neither the total luciferase values in the vehicle condition nor the values following 
enzalutamide suppression were significantly different between the two groups (data not shown). 
However, spiking with enzalutamide resulted in a significant signal suppression (Δ suppression, 
defined as the total luciferase activity with vehicle minus values after enzalutamide suppression i.e. 
how much the signal can be suppressed by a potent AR antagonist) in 17/23 ADT patients vs. 0/6 
Synth-I patients (χ² P=0.001) (Fig. 5C). We reasoned that the total luciferase activity (without 
enzalutamide) consists on the one hand of the Δ suppression (the amount of decrease in the 
luciferase signal due to enzalutamide) which represents the true AR bioactivity in patients with very 
low androgen levels, whereas the remaining luciferase activity after enzalutamide suppression is 
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determined by other (matrix) effects. In other words, total serum luciferase activity = Δ suppression (or 
androgen effect) + background signal (or matrix effect). This was supported by two elements. Firstly, 
serum T concentrations were significantly lower in ADT patients without (n=6) vs. with significant 
further Δ suppression (n=16, P=0.04 by Mann-Whitney test) (Fig. 5D), indicating that Δ suppression 
represents the true residual androgen bioactivity in these patients. Importantly, the bioactivity in 2/3 
ADT patients with serum T below the LC-MS/MS limit of quantification could still be further suppressed 
by enzalutamide (vs. 0/6 with Synth-I, χ² P=0.02), suggesting that androgen bioactivity may not always 
be completely suppressed in ADT patients with undetectable total T concentrations. Along the same 
lines, Δ suppression correlated significantly (although weakly) with calculated free T and bioT (R² = 
0.48 and 0.47 respectively, both P<0.0001) (Fig. 5E, F). Serum total T levels also correlated 
significantly with Δ suppression (R² = 0.42, P=0.0001), although only weakly with total luciferase 
values (R² = 0.25, P=0.005) and not with enzalutamide-suppressed (“baseline”) values (data not 
shown). Thus, our hypothesis that the androgen bioactivity in these samples could be gauged from Δ 
suppression was supported. Secondly, there was a good correlation (P<0.0001, R² = 0.66) between 
total luciferase readings without enzalutamide and the Δ suppression (Fig. 5G). This graph allows 
identification of samples with below (pat. 15) or above average (pat. 11, 23 and 45) readouts in Fig. 5B 
(i.e. samples with negative or positive matrix effects). 
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Fig. 5. Pilot study on androgen bioactivity in prostate cancer patients. 
A. Serum total T concentrations in different treatment groups. The LC-MS/MS limit of quantification (LOQ) (5 
ng/dL) is indicated by the horizontal dotted line. Individual values are plotted along with mean ± SEM values. ** = 
P ≤ 0.01, *** = P ≤ 0.001 by Dunn’s multiple comparisons test (after Kruskal-Wallis test, overall P ≤ 0.001). 
B. Bland-Altman methods comparison showing relative deviation (in %) of serum total T measurements by 
immunoassay plotted against the average of LC-MS/MS and immunoassay results. The LC-MS/MS LOQ is 
indicated by the vertical dotted line. 
C. Arbitrary luciferase unit (ALU) values of ADT or Synth-I treatment groups. Pre-ADT patient sample (nr. 50) 
shown for reference. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P < 0.0001 for each sample with 10
-5
 M 
enzalutamide compared to its vehicle-spiked control. Analysis by two-way RM ANOVA with differences between 
samples, effect of enzalutamide as well as interaction effect all P ≤ 0.0001. 
D..T serum concentrations in ADT patients with (n=17) or without (n=6) significant residual androgen bioactivity as 
shown in panel C (n=23 ADT patients in total). * = P = 0.04 by Mann-Whitney test. 
21/32 
 
E, F. Correlation of bioT and free T with Δ suppression. The 95% confidence band of the linear regression is 
shown as a dotted line.  
G. Correlation of total ALU values with Δ suppression. The 95% confidence band of the linear regression is shown 
as a dotted line, and significant outlier samples are identified by number (compare with panel C). 
4. DISCUSSION 
Several in vitro androgen bioassays have been previously established and applied to analyze serum 
from older men (Need et al., 2010, Raivio et al., 2002), women (Chen et al., 2006), children (Paris et 
al., 2002b, Raivio et al., 2001, Raivio et al., 2004), hyperandrogenic women or children (Hero et al., 
2005, Liimatta et al., 2014, Roy et al., 2006) or prostate cancer patients (Raivio et al., 2003, Rannikko 
et al., 2006), for example. In our hands, optimal assay characteristics were achieved using full-length 
human AR (Christiaens et al., 2005) and a classical ARE (Suppl. Fig. 1) (Denayer et al., 2010). The 
specificity of our cell line (Fig. 1B) was in line with previous cell lines using classical AREs, although 
most others have reported better sensitivity (Blankvoort et al., 2001, Chen et al., 2006, Paris et al., 
2002b, Raivio et al., 2001, Roy et al., 2004, Roy et al., 2006, Sonneveld et al., 2005, Terouanne et al., 
2000). However, this may be due to the use of steroid extraction procedures as well as serum dilution 
in other assays, given that others who have used undiluted serum have reported a sensitivity similar to 
ours (Need et al., 2010). Another group recently reported a selective ARE-based system with 
sensitivity similar to what we report here (Campana et al., 2016). Since classical AREs have greatest 
significance in vivo (Schauwaers et al., 2007), we do not consider selective AREs a prerequisite for 
“specific” androgen bioassays (Campana et al., 2015). In our view, the advantage of bioassays is their 
broad-spectrum ability to provide an integrated readout of AR agonist and antagonist activity without a 
priori knowledge of their structure, unlike other methods e.g. mass spectrometry which are already 
highly sensitive and specific. 
Our main finding was that SHBG directly suppresses androgen bioactivity and correlated well with 
bioavailable or free T concentrations (Fig. 3, Fig. 4). Importantly however, the effect of SHBG on in 
vitro AR bioactivity was no longer maintained when serum was diluted more than tenfold (Fig. 2A), 
whereas most previous AR bioassays have used 1-10% serum conditions. It is known that dilution 
influences the equilibrium between SHBG and T in other types of assays e.g. in equilibrium dialysis 
(Van Uytfanghe et al., 2004), and our findings are remarkably similar. One previous study also used 
undiluted serum (Need et al., 2010) although incubation of cells with serum was limited to only five 
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minutes. Our findings show that a HEK293 cell-based assay as previously used by others (Chen et al., 
2006, Roy et al., 2006, Wilkinson et al., 2008) offers the advantage of not only lacking significant 
endogenous steroid metabolism, but also being quite robust and able to withstand overnight 
incubation in 100% serum with minimal effects on luciferase activity, cell viability or cytotoxicity (Fig. 2 
C-E, G-H). Only proliferation was significantly reduced at 100% compared to 10% serum conditions 
(Fig. 2F), which may in fact be considered beneficial for a transcription-based reporter (rather than a 
proliferation) bioassay. 
A trade-off of using undiluted serum may be an increased likelihood of matrix effects, although these 
have also been noted in previous studies. To circumvent this problem, (Roy et al., 2006) used diethyl 
ether extraction whereas (Paris et al., 2002a) compared samples to patient-specific standard curves in 
steroid-depleted serum. However, either approach likely removes the influence of SHBG, which is a 
crucial determinant of inter-individual differences in circulating androgen bioactivity. We observed that 
spiking with either 10
-5
 M of the potent anti-androgen enzalutamide or 10
-6
 M of DHT or R1881 
resulted in respectively minimal and maximal luciferase values which differed between different human 
serum samples as well as between human serum samples and DCC-FCS (Fig. 5C, Suppl. Fig. 3). 
We made use of these differences to adjust for such matrix effects mathematically, similar to what is 
commonly used in dual-luciferase assays or when adjusting for transfection efficiency in transient 
transfection assays. 
Although AR bioassays are unlikely to become sufficiently standardized to play a role in routine clinical 
chemistry (Rosner, 2001), they may offer physiologically useful insights in research settings. Their 
primary niche is, in our opinion, any situations in which serum T concentrations alone may be 
unreliable to assess androgen status, e.g. to detect abuse of synthetic androgens (Fig. 1B) 
(Cadwallader et al., 2011, Cooper et al., 2013). Another example is DHT treatment in elderly men, 
which reduces serum T levels but clearly increases androgen bioactivity (Raivio et al., 2002). Patients 
with altered SHBG concentrations or binding affinities may represent a similar challenging 
circumstance in which serum total T levels may be misleading (Keevil et al., 2016, Ohlsson et al., 
2011). Analysis of serum from a recently described SHBG-deficient man (Vos et al., 2014) with low 
total T but low-normal free T (Wu et al., 2010) showed in vitro androgen bioactivity in the low-normal 
range (Fig. 3A, compared to Fig. 4A-B) although our pilot studies are underpowered to formally 
establish normal reference values for our assay. As expected, we found that AR bioactivity correlated 
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more with bioT or free T than with total T in men with variable SHBG concentrations (Fig. 4C-E). A 
similar degree of correlation with free T has been observed with other measurements like salivary T 
(Fiers et al., 2014, Keevil et al., 2014). Furthermore, bioactivity in our assay was less suppressed by 
SHBG mutants with severely reduced (R123H) or completely absent androgen binding (S42L) (Hong 
et al., 2011, Ohlsson et al., 2011, Wu and Hammond, 2014), although bioassays may not be sensitive 
enough to detect subtle differences from SHBG mutants like P156L, which increased free T by 22% in 
one study (Ohlsson et al., 2011). 
Importantly, our study found a significant but only very modest correlation between AR bioassay 
results and calculated free T or bioT results, similar to what others have reported previously using 
other formulas e.g. the free androgen index (Liimatta et al., 2014). Thus, although SHBG decreases 
free T concentrations in vitro (Van Uytfanghe et al., Clin Chem 2004) and we now show the same for 
AR bioassays, this should by no means be taken to imply that AR bioassays are measuring free T 
concentrations or correlate well with free T measurements. In fact our data confirm previous findings 
that the correlation between bioassay results and calculated free T or bioT is quite poor. Although 
different formulas or direct measurements may have limitations in terms of accurately reflecting free T 
concentrations, the main reason for this poor correlation with bioassays is probably that AR bioassays 
are measuring a very different, multifactorial signal which cannot simply be compared to free T 
concentrations. There are growing concerns surrounding the way free T is currently applied in clinical 
practice (Bhasin, 2016, Laurent and Vanderschueren, 2014, Zakharov et al., 2015). Efforts are 
ongoing to resolve the unmet clinical need of adequate determinations or formulas for free T 
concentrations but until there is consensus on this issue, the relationship between golden standard 
free or bioT concentrations and bioassay results cannot be investigated further. 
AR bioassays may also be useful to assess androgen status in patients taking anti-androgens. A well 
known effect of anti-androgens is that they increase serum T concentrations via hypothalamic 
feedback, even though they reduce net androgen bioactivity. This caveat may apply particularly to 
patients taking CPA, which has both anti-androgenic, anti-gonadotropic and progestagenic effects. In 
line with this hypothesis, we found that androgen bioactivity is indeed more reduced than serum T 
levels in CPA-treated men (Fig. 4A). Perhaps more importantly, we found residual androgen 
bioactivity in prostate cancer patients receiving ADT (Fig. 5C) but not Synth-I treatment. Previous 
studies have shown the importance of incompletely suppressed T serum concentrations during ADT, 
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although there is some debate whether concentrations < 50, 32 or 20 ng/dL are optimal (Morote et al., 
2007, Morote et al., 2016, van der Sluis et al., 2012a, van der Sluis et al., 2012b). Except for one 
patient, all men receiving ADT or ADT+Bic in our sample had serum T concentrations < 20 ng/dL, 
whereas concentrations < 50 ng/dL are already conventionally considered “castrate” levels. In 
contrast, all six patients receiving Synth-I treatment had undetectable serum T concentrations. 
Moreover, these novel agents not only reduce circulating androgen concentrations more completely, 
but also interfere with intratumoral androgen metabolism.  Based on our pilot findings, we suggest 
further research to investigate whether residual circulating androgen bioactivity during ADT contributes 
to the development of castration-resistant prostate cancer and/or may be amenable or predictive of 
response to treatment with novel androgen synthesis inhibitors. However, it should be noted that 
bioassays can only assess circulating bioactivity which does not necessarily reflect androgen 
bioactivity within tissues. 
In summary, in vitro androgen reporter bioassays are useful tools to study how androgen bioactivity in 
serum is determined not only by androgens and anti-androgens but also by SHBG. Furthermore, we 
show that excessive serum dilution decreases the suppressive effect of SHBG on androgen bioactivity 
and that appropriate attention should also be paid to matrix effects. Importantly, we found differences 
in residual androgen bioactivity in prostate cancer patients under treatment with ADT or Synth-I. The 
clinical significance of these findings need further investigation. 
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